CRISPR Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CRISPR Therapeutics (CRSP).

Price Target Range — 12 Quarters

Analyst Consensus — 23 Analysts

2S.Buy

11Buy

9Hold

1Sell

Consensus RatingBuy# Analysts23Avg. Consensus PT$72Upside to Avg. PT+29.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
Aug 31, 2026	Needham	Gil Blum	Maintained	Buy	$82
Aug 25, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
Aug 4, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$82→$88
Jul 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$80
Jul 6, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$50→$56
May 6, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$80→$82
Mar 17, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$105→$110
Feb 17, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$74→$76
Feb 13, 2026	TD Cowen	Tyler Van Buren	PT Raise	Hold	$40→$45
Feb 13, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$62→$74
Feb 13, 2026	Needham	Gil Blum	PT Raise	Buy	$80→$82
Jan 30, 2026	Citizens	Silvan Turkcan	PT Cut	Market Outperform	$86→$80
Dec 23, 2025	Needham	Gil Blum	Maintained	Buy	$80
Dec 23, 2025	Citizens	Silvan Tuerkcan	Maintained	Market Outperform	$86
Nov 26, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$82→$74
Nov 12, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$87→$77
Nov 11, 2025	RBC Capital	Luca Issi	PT Raise	Sector Perform	$42→$50
Nov 11, 2025	Baird	Jack Allen	PT Cut	Neutral	$52→$44

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Benzinga Newsdesk

CRISPR Therapeutics AG

ニュース

パートナーシップ

ベンジンガ・グローバル

CRISPR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

CRISPR Therapeutics AG

ニュース

パートナーシップ

ベンジンガ・グローバル

CRISPR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRONeedham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PROCitigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PROHC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target